International Urology and Nephrology

, Volume 47, Issue 2, pp 243–248 | Cite as

Evaluation of the utility of different scoring systems (FGSI, LRINEC and NLR) in the management of Fournier’s gangrene

  • Ozan Bozkurt
  • Volkan Sen
  • Omer Demir
  • Adil Esen
Urology - Original Paper



To evaluate the mortality and morbidity prediction capability of three different scoring systems: Fournier’s gangrene severity index (FGSI), Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) and neutrophile–lymphocyte ratio (NLR) with this retrospective cohort study.


Medical records of all patients treated for FG with the final histopathological diagnosis between October 2008 and January 2013 were retrospectively evaluated. Data were collected from medical history, physical examination findings, biochemical and microbiological tests and tissue cultures. FGSI and LRINEC scores and NLR were determined for all patients. Then, it was explored whether higher FGSI (<4 vs. ≥4), LRINEC (<6 vs. ≥6) or NLR (<10 vs. ≥10) were associated with worse prognosis.


A total of 33 patients were evaluated; 3 died (9.1 %) and 30 (90.9 %) survived. Mean age was 57.6 ± 13.2 years. Survivors were younger than nonsurvivors (56 ± 12.8 vs. 72.9 ± 7.3, p < 0.05). Diabetes mellitus was the most encountered predisposing factor with 66.7 % prevalence. All patients with localized disease (100 %) and 8/11 patients (72.7 %) with extended disease survived (p < 0.05). Patients with higher FGSI scores, LRINEC scores and NLR were more likely to require mechanical ventilation in intensive care unit and longer hospitalization times and were more likely to die compared to patients with lower scores.


In conclusion, all evaluated scoring systems, FGSI, LRINEC and NLR, are capable of pointing out worse prognosis including mechanical ventilation requirement and mortality. NLR has the advantage of its rapid, simple and low-cost characteristics.


Fournier’s gangrene FGSI LRINEC Neutrophile–lymphocyte ratio 


Conflict of interest

The authors have no conflict of interest to declare.


  1. 1.
    Fournier JA (1883) Gangrene foudroyante de la verge. Semin Med 3:345Google Scholar
  2. 2.
    Shyam DC, Rapsang AG (2013) Fournier’s gangrene. Surgeon 11(4):222–232. doi: 10.1016/j.surge.2013.02.001 PubMedCrossRefGoogle Scholar
  3. 3.
    Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI (1995) Outcome prediction in patients with Fournier’s gangrene. J Urol 154(1):89–92PubMedCrossRefGoogle Scholar
  4. 4.
    Wong CH, Khin LW, Heng KS, Tan KC, Low CO (2004) The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 32:1535–1541PubMedCrossRefGoogle Scholar
  5. 5.
    Zahorec R (2001) Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5–14PubMedGoogle Scholar
  6. 6.
    De Jager CP, van Wijk PT, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC (2010) Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care 14:R192. doi: 10.1186/cc9309 PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Yeniyol CO, Suelozgen T, Arslan M, Ayder AR (2004) Fournier’s gangrene: experience with 25 patients and use of Fournier’s gangrene severity index score. Urology 64:218–222PubMedCrossRefGoogle Scholar
  8. 8.
    Erol B, Tuncel A, Hanci V, Tokgoz H, Yildiz A, Akduman B, Kargi E, Mungan A (2010) Fournier’s gangrene: overview of prognostic factors and definition of new prognostic parameter. Urology 75:1193–1198. doi: 10.1016/j.urology.2009.08.090 PubMedCrossRefGoogle Scholar
  9. 9.
    Sorensen MD, Krieger JN, Rivara FP, Broghammer JA, Klein MB, Mack CD, Wessells H (2009) Fournier’s gangrene: population based epidemiology and outcomes. J Urol 181:2120–2126. doi: 10.1016/j.juro.2009.01.034 PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Benjelloun EB, Souiki T, Yakla N, Ousadden A, Mazaz K, Louchi A, Kanjaa N, Taleb KA (2013) Fournier’s gangrene: our experience with 50 patients and analysis of factors affecting mortality. World J Emerg Surg 8(1):13. doi: 10.1186/1749-7922-8-13 PubMedCentralCrossRefGoogle Scholar
  11. 11.
    Dahm P, Roland FH, Vaslef SN, Moon RE, Price DT, Georgiade GS, Vieweg J (2000) Outcome analysis in patients with primary necrotizing fasciitis of the male genitalia. Urology 56(1):31–35PubMedCrossRefGoogle Scholar
  12. 12.
    Spirnak JP, Resnick MI, Hampel N, Persky L (1984) Fournier’s gangrene: a report of 20 patients. J Urol 131(2):289–291PubMedGoogle Scholar
  13. 13.
    Clayton MD, Fowler JE Jr, Sharifi R, Pearl RK (1990) Causes, presentation and survival of fifty-seven patients with necrotizing fasciitis of the male genitalia. Surg Gynecol Obstet 170(1):49–55PubMedGoogle Scholar
  14. 14.
    Nisbet AA, Thompson IM (2002) Impact of diabetes mellitus on the presentation and outcomes of Fournier’s gangrene. Urology 60:775–779PubMedCrossRefGoogle Scholar
  15. 15.
    Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, Baspinar I (2006) Fournier’s gangrene: risk factors and strategies for management. World J Surg 30:1750–1754PubMedCrossRefGoogle Scholar
  16. 16.
    Morua AG, Lopez JA, Garcia JD, Montelongo RM, Guerra LS (2009) Fournier’s gangrene: our experience in 5 years, bibliography review and assessment of the Fournier’s gangrene severity index. Arch Esp Urol 62(7):532–540PubMedGoogle Scholar
  17. 17.
    Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies BJ (2008) Validation of the Fournier’s gangrene severity index in a large contemporary series. J Urol 180(3):944–948. doi: 10.1016/j.juro.2008.05.021 PubMedCrossRefGoogle Scholar
  18. 18.
    Tuncel A, Aydin O, Tekdogan U, Nalcacioglu V, Capar Y, Atan A (2006) Fournier’s gangrene: three years of experience with 20 patients and validity of the Fournier’s Gangrene Severity Index Score. Eur Urol 50(4):838–843PubMedCrossRefGoogle Scholar
  19. 19.
    Janane A, Hajji F, Ismail TO, Chafiqui J, Ghadouane M, Ameur A, Abbar M, Albouzidi A (2011) Hyperbaric oxygen therapy adjunctive to surgical debridement in management of Fournier’s gangrene: usefulness of a severity index score in predicting disease gravity and patient survival. Actas Urol Esp 35(6):332–338. doi: 10.1016/j.acuro.2011.01.019 PubMedCrossRefGoogle Scholar
  20. 20.
    Roghmann F, von Bodman C, Löppenberg B, Hinkel A, Palisaar J, Noldus J (2012) Is there a need for the Fournier’s gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier’s gangrene. BJU Int 110(9):1359–1365. doi: 10.1111/j.1464-410X.2012.11082.x PubMedCrossRefGoogle Scholar
  21. 21.
    Backhaus M, Citak M, Tilkorn DJ, Meindl R, Schildhauer TA, Fehmer T (2011) Pressure sores significantly increase the risk of developing a Fournier’s gangrene in patients with spinal cord injury. Spinal Cord 49(11):1143–1146. doi: 10.1038/sc.2011.75 PubMedCrossRefGoogle Scholar
  22. 22.
    Kahramanca S, Kaya O, Ozgehan G, Irem B, Dural I, Küçükpınar T, Kargıcı H (2014) Are neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as effective as Fournier’s gangrene severity index for predicting the number of debridements in Fourner’s gangrene? Ulus Travma Acil Cerrahi Derg 20(2):107–112. doi: 10.5505/tjtes.2014.62829 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Ozan Bozkurt
    • 1
  • Volkan Sen
    • 1
  • Omer Demir
    • 1
  • Adil Esen
    • 1
  1. 1.Department of UrologyDokuz Eylul University School of MedicineInciralti, IzmirTurkey

Personalised recommendations